Literature DB >> 26068297

Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.

P D'Amelio1, F Sassi2, I Buondonno2, G Fornelli2, E Spertino2, L D'Amico3, M Marchetti2, M Lucchiari4, I Roato3, G C Isaia2.   

Abstract

UNLABELLED: We evaluated the effect of parathyroid hormone (PTH) on Wnt10b production by immune system cells in humans. We showed that bone anabolic effect of intermittent PTH treatment may be amplified by T cells through increased production of Wnt10b. Chronic increase in PTH as in primary hyperparathyroidism does not increase Wnt10b expression.
INTRODUCTION: The aim of this study is to assess the effect of PTH on Wnt10b production by immune system cells in humans. We assessed both the effect of intermittent PTH administration (iPTH) and of chronic PTH hypersecretion in primary hyperparathyroidism (PHP).
METHODS: Eighty-two women affected by post-menopausal osteoporosis were randomly assigned to treatment with calcium and vitamin D alone (22) or plus 1-84 PTH (42), or intravenous ibandronate (18). Wnt10b production by unfractioned blood nucleated cells and by T, B cells and monocytes was assessed by real-time RT-PCR and ELISA at baseline, 3, 6, 12 and 18 months of treatment. The effect of chronic elevation of PTH was evaluated in 20 patients affected by PHP at diagnosis and after surgical removal of parathyroid adenoma. WNT10b from both osteoporotic and PHP patients was compared to healthy subjects matched for age and sex.
RESULTS: iPTH increases Wnt10b production by T cells, whereas PHP does not. After surgical restoration of normal parathyroid function, WNT10b decreases, although it is still comparable with healthy subjects' level. Thus, chronic elevation of PTH does not significantly increase WNT10b production as respect to control.
CONCLUSIONS: This is the first work showing the effect of both intermittent and chronic PTH increase on Wnt10b production by immune system cells. We suggest that, in humans, T cells amplified the anabolic effect of PTH on bone, by increasing Wnt10b production, which stimulates osteoblast activity.

Entities:  

Keywords:  Immune system; Osteoporosis; PTH; Primary hyperparathyroidism; T cells; Wnt10b

Mesh:

Substances:

Year:  2015        PMID: 26068297     DOI: 10.1007/s00198-015-3189-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  26 in total

Review 1.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

2.  The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure.

Authors:  M Parisien; S J Silverberg; E Shane; L de la Cruz; R Lindsay; J P Bilezikian; D W Dempster
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

3.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.

Authors:  T Bellido; A A Ali; I Gubrij; L I Plotkin; Q Fu; C A O'Brien; S C Manolagas; R L Jilka
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

4.  The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b.

Authors:  Jau-Yi Li; Lindsey D Walker; Abdul Malik Tyagi; Jonathan Adams; M Neale Weitzmann; Roberto Pacifici
Journal:  J Bone Miner Res       Date:  2014-01       Impact factor: 6.741

5.  Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study.

Authors:  M-S M Ardawi; A M Al-Sibiany; T M Bakhsh; A A Rouzi; M H Qari
Journal:  Osteoporos Int       Date:  2011-10-28       Impact factor: 4.507

6.  Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.

Authors:  S Piemonte; E Romagnoli; C Bratengeier; W Woloszczuk; A Tancredi; J Pepe; C Cipriani; S Minisola
Journal:  J Endocrinol Invest       Date:  2012-07-24       Impact factor: 4.256

7.  Targeted deletion of Sost distal enhancer increases bone formation and bone mass.

Authors:  Nicole M Collette; Damian C Genetos; Aris N Economides; LiQin Xie; Mohammad Shahnazari; Wei Yao; Nancy E Lane; Richard M Harland; Gabriela G Loots
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-10       Impact factor: 11.205

8.  Parathyroid hormone-related peptide modulates signal pathways in skin and hair follicle cells.

Authors:  M Thomson; J McCarroll; J Bond; C Gordon-Thomson; E D Williams; G P M Moore
Journal:  Exp Dermatol       Date:  2003-08       Impact factor: 3.960

9.  Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH.

Authors:  Vaibhav Saini; Dean A Marengi; Kevin J Barry; Keertik S Fulzele; Erica Heiden; Xiaolong Liu; Christopher Dedic; Akira Maeda; Sutada Lotinun; Roland Baron; Paola Divieti Pajevic
Journal:  J Biol Chem       Date:  2013-06-02       Impact factor: 5.157

10.  Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis.

Authors:  M Parisien; R W Mellish; S J Silverberg; E Shane; R Lindsay; J P Bilezikian; D W Dempster
Journal:  J Bone Miner Res       Date:  1992-08       Impact factor: 6.741

View more
  7 in total

1.  Parathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota.

Authors:  Jau-Yi Li; Mingcan Yu; Subhashis Pal; Abdul Malik Tyagi; Hamid Dar; Jonathan Adams; M Neale Weitzmann; Rheinallt M Jones; Roberto Pacifici
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 2.  Regulation of Bone Remodeling by Parathyroid Hormone.

Authors:  Marc N Wein; Henry M Kronenberg
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

3.  Cytokine and hormonal regulation of bone marrow immune cell Wnt10b expression.

Authors:  Fraser L Collins; Naiomy Deliz Rios-Arce; Laura R McCabe; Narayanan Parameswaran
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

Review 4.  Role of Gut Microbiota in the Skeletal Response to PTH.

Authors:  Roberto Pacifici
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

5.  Editorial: Updates on Osteoimmunology: What's New on the Crosstalk Between Bone and Immune Cells.

Authors:  Giacomina Brunetti; Patrizia D'Amelio; Giorgio Mori; Maria Felicia Faienza
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-20       Impact factor: 5.555

6.  Hypoalbuminemia differently affects the serum bone turnover markers in hemodialysis patients.

Authors:  Cai Mei Zheng; Chia Chao Wu; Chien Lin Lu; Yi Chou Hou; Mai Szu Wu; Yung Ho Hsu; Remy Chen; Tian Jong Chang; Jia Fwu Shyu; Yuh Feng Lin; Kuo Cheng Lu
Journal:  Int J Med Sci       Date:  2019-10-21       Impact factor: 3.738

7.  The Role of T Cells Reactive to the Cathelicidin Antimicrobial Peptide LL-37 in Acute Coronary Syndrome and Plaque Calcification.

Authors:  Fernando Chernomordik; Bojan Cercek; Wai Man Lio; Peter M Mihailovic; Juliana Yano; Romana Herscovici; Xiaoning Zhao; Jianchang Zhou; Kuang-Yuh Chyu; Prediman K Shah; Paul C Dimayuga
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.